Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/spandidos-publications/inhibition-of-gp130-stat3-and-emt-by-combined-bazedoxifene-and-P7D0O93hc3
References (39)
-
(2000)
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptorsOncogene, 19
-
(2005)
Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptorNat Struct Mol Biol, 12
-
(2018)
IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasisCancer Manag Res, 10
-
(2007)
Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironmentNat Rev Immunol, 7
-
(2014)
Interleukin-6 and its receptors: A highly regulated and dynamic systemCytokine, 70
-
(2015)
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): A randomised, open-label, phase 2 trialLancet Oncol, 16
-
(2020)
Bazedoxifene enhances paclitaxel efficacy to suppress glioblastoma via altering Hippo/YAP pathwayJ Cancer, 11
-
(1999)
Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cellsLeukemia, 13
-
(2002)
Paclitaxel in cancer therapyExpert Opin Pharmacother, 3
-
(2018)
Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer: A randomized clinical trialJAMA Oncol, 4
-
(2014)
Molecular pathways: IL11 as a tumor-promoting cytokine-translational implications for cancersClin Cancer Res, 20
-
(2016)
Bazedoxifene as a novel GP130 inhibitor for pancreatic cancer therapyMol Cancer Ther, 15
-
(2009)
Inflammation and cancer: IL-6 and STAT3 complete the linkCancer Cell, 15
-
(2000)
Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cellsGynecol Oncol, 79
-
(2014)
Ovarian cancer cell line panel (OCCP): Clinical importance of in vitro morphological subtypesPLoS One, 9
-
(2015)
A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130J Immunol, 195
-
(2021)
Bazedoxifene, a GP130 inhibitor, modulates EMT signaling and exhibits antitumor effects in HPV-positive cervical cancerInt J Mol Sci, 22
-
(2012)
Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancerCurr Pharm Des, 18
-
(2003)
Mechanisms of taxol resistance related to microtubulesOncogene, 22
-
(2013)
Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancerMol Cancer Ther, 12
-
(2018)
Cancer statistics, 2018CA Cancer J Clin, 68
-
(2004)
Acquiring signalling specificity from the cytokine receptor gp130Trends Genet, 20
-
(2002)
Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: The receptor is crucial for kinase activationBiochem J, 361
-
(2018)
Interleukin-6 family cytokinesCold Spring Harb Perspect Biol, 10
-
(2001)
Proliferation, cell cycle and apoptosis in cancerNature, 411
-
(2019)
Correction to: Bazedoxifene as a novel GP130 inhibitor for colon cancer therapyJ Exp Clin Cancer Res, 38
-
(2014)
The IL-6 feed-forward loop: A driver of tumorigenesisSemin Immunol, 26
-
(2009)
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumoursNature, 457
-
(2018)
The role of the interleukin (IL)-6/IL-6 receptor axis in cancerBiochem Soc Trans, 46
-
(1998)
Cisplatin-and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53Mol Pharmacol, 53
-
(1998)
Paclitaxel-induced apoptosis is associated with expression and activation of c-Mos gene product in human ovarian carcinoma SKOV3 cellsCancer Res, 58
-
(2019)
Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancerBreast Cancer Res Treat, 175
-
(2016)
Potential therapeutic implications of IL-6/IL-6R/gp130-targeting agents in breast cancerOncotarget, 7
-
(2019)
Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancerCancer Lett, 448
-
(2002)
Stats: Transcriptional control and biological impactNat Rev Mol Cell Biol, 3
-
(2009)
CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cellsCancer Chemother Pharmacol, 63
-
(2019)
Pleiotropy and specificity: Insights from the interleukin 6 family of cytokinesImmunity, 50
-
(2014)
Drug design targeting protein-protein interactions (PPIs) using multiple ligand simultaneous docking (MLSD) and drug repositioning: Discovery of raloxifene and bazedoxifene as novel inhibitors of IL-6/GP130 interfaceJ Med Chem, 57
-
(2008)
Knockdown of STAT3 by shRNA inhibits the growth of CAOV3 ovarian cancer cell line in vitro and in vivoActa Biochim Biophys Sin (Shanghai), 40
- Publisher
- Spandidos Publications
- Copyright
- Copyright © 2022 Spandidos Publications
- ISSN
- 1021-335X
- DOI
- 10.3892/or.2022.8263
Abstract
The interleukin 6 (IL‑6)/glycoprotein 130 (GP130)/signal transducer and activator of transcription 3 (STAT3) signalling pathway, with GP130 as an intermediate membrane receptor, is involved in the survival, metastasis, and resistance of ovarian cancer. Bazedoxifene, an FDA‑approved drug, is an inhibitor of GP130 and a selective estrogen modulator (SERM). We studied the mechanism of the combination therapy of bazedoxifene and paclitaxel in inhibiting the IL‑6‑mediated GP130/STAT3 signaling pathway in ovarian cancer. Surface plasmon resonance (SPR) was used to assess the binding of bazedoxifene to GP130. Migration, invasion, and apoptosis of ovarian cancer cells were assessed using bazedoxifene and paclitaxel. In addition, we determined the effects of bazedoxifene and paclitaxel alone or in combination on the GP130/STAT3 pathway and epithelial‑mesenchymal transition (EMT). The results revealed that the combination of bazedoxifene and paclitaxel suppressed cell viability, migration, and invasion in the ovarian cancer cells. In addition, the combination treatment increased apoptosis. Furthermore, bazedoxifene combined with paclitaxel inhibited the growth of ovarian cancer cells in a xenograft tumour model. This combination reduced STAT3 phosphorylation and suppressed gene expression and EMT. In conclusion, inhibition of GP130/STAT3 signalling and EMT via a combination of bazedoxifene and paclitaxel could be used as a therapeutic strategy by which to overcome ovarian cancer.
Journal
Oncology Reports – Spandidos Publications
Published: Mar 10, 2022